Combined therapy for treatment of HIV infection

Details Combined therapy for treatment of HIV infection Combined therapy for treatment of HIV infection

2006-08-22

2006-08-22

Housel, James (Department: 1648)

Drug, bio-affecting and body treating compositions

Nonspecific immunoeffector, per se ; or nonspecific...

C514S002600, C514S015800, C530S300000, C536S028540

Reexamination Certificate

active

07094413

ABSTRACT:
The present invention relates to pharmaceutical preparations and methods for treating individuals infected with the human immunodeficiency virus (HIV). The pharmaceutical preparations comprise an immunomodulating agent and a anti-retroviral compound. The pharmaceutical preparations are used to treat HIV infected patients, particularly for gastrointestinal complications arising from viral infection. In addition, the pharmaceutical preparations of the present invention have the effect of raising the levels of CD4+single positive and CD4+and CD8+double positive T cells, thus promoting restoration and normalization of the immune system following HIV infection.

REFERENCES:
patent: 5385888 (1995-01-01), Goodenow et al.
patent: 5723128 (1998-03-01), Clayberger et al.
patent: 5753625 (1998-05-01), Buelow
patent: 6162434 (2000-12-01), Buelow et al.
patent: 6696545 (2004-02-01), Buelow et al.
patent: WO 88/05784 (1988-08-01), None
patent: WO 90/10016 (1990-09-01), None
patent: WO 93/08817 (1993-05-01), None
patent: WO 93/17699 (1993-09-01), None
patent: WO 94/02162 (1994-02-01), None
patent: WO 95/13288 (1995-05-01), None
patent: WO 96/22306 (1996-07-01), None
patent: WO 96/35443 (1996-11-01), None
patent: WO 97/24140 (1997-07-01), None
patent: WO 97/44052 (1997-11-01), None
patent: WO 97/44351 (1997-11-01), None
patent: WO 98/46633 (1998-10-01), None
Kaminski et al. (from IDS, Alternative Medicine Rev. 1998 vol. 3, No. 1, pp. 40-53.
Alkhatib, G., et al., “CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage topic HIV-1,”Science272(5270):1955-1958 (Jun. 1996).
Autran, B., et al., “Positive Effects of Combined Antiretroviral Therapy on CD4+ T Cell Homeostasis and Function in Advanced HIV Disease,”Science277(5322):112-116 (Jul. 1997).
Benveniste, O., et al., “Interleukin 1 β, interleukin 6, tumor necrosis factor α, and interleukin 10 responses in peripheral blood mononuclear cells of cynomolgus macaques during acute infection with SIVmac251,”AIDS Res. Hum. Retroviruses12(3):241-250 (Feb. 1996).
Biswas, D.K., et al., “Inhibition of HIV-1 replication by combination of a novel inhibitor of TNF-α with AZT,”J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18(5):426-434 (Aug. 1998).
Blaese, R.M., et al., “Gene Therapy for Primary Immunodeficiency Disease,”Immunodefic. Rev. 3(4):329-349 (1992).
Bogner, J.R., et al., “Th1/Th2 shift in HIV lymph nodes: no contribution of CD60 cells,”Infection29(1):32-36 (Jan.-Feb. 2001).
Boismenu, R., et al., “Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis,”Ann Rheum. Dis. 61 Suppl. 2:ii19-24 (Nov. 2002).
Buelow, R., et al., “Immunomodulation by soluble HLA class I,”Transplantation59(5):649-654 (Mar. 1995).
Buelow, R., et al., “Prolongation of skin allograft survival in mice following administration of ALLOTRAP,”Transplantation59(4);455-460 (1995).
Cantoni, L., et al., “Interleukin-1 and tumour necrosis factor induce hepatic heme oxygenase feedback regulation by glucocorticoids,”Biochem. J. 279(Pt 3):891-894 (1991).
Chêne, L., et al., “Thymocyte-Thymic Epithelial Cell Interaction Leads to High-Level Replication of Human Immunodeficiency Virus Exclusively In Mature CD4+CD8−CD3+Thymocytes: a Critical Role for Tumor Necrosis Factor and Interleukin-7,”J. Virol. 73(9):7533-7542 (Sep. 1999).
Clayette, P., et al., “Effects of RP 55778, a tumor necrosis factor alpha synthesis inhibitor, on antiviral activity of dideoxynucleosides,”Antimicrob. Agents Chemother. 41(4):875-877 (Apr. 1997).
Cuturi, M.C., et al., “Prolongation of Allogeneic Heart Graft Survival in Rats by Administration of a Peptide (a.a. 75-84) from the Alpha 1 Helix of the First Domain of HLA-B7 01,”Transplantation59(5):661-669 (1995).
Dalgleish, A., et al., “The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus,”Nature312(5996):763-767 (Jan. 1984).
De Waal Malefyt, R., et al., “Interleukin 10 (IL-10) Inhibits Cytokine Synthesis by Human Monocytes: An Autoregulatory Role of IL-10 Produced by Monocytes,”J. Exp. Med. 174(5):1209-1222 (Nov. 1991).
Feng, Y., et al., “HIV-1 entry cofactor: functional cDNA cloning of a seven transmembrane, G protein-coupled receptor,”Science272(5263):872-877 (May 1996).
Fiorentino, D., et al., “IL-10 inhibits cytokine production by activated macrophages,”J. Immunol. 147(11):3815-3822 (Dec. 1991).
Fujinaga, K., et al., “Generation of endogenous tumour necrosis factor-alpha in MOLT-4 cells during the acute replication phase of human immunodeficiency virus type 1 determines the subsequent latent infection,”J. Gen. Virol. 79(Pt 2):221-229 (Feb. 1998).
Gao, L., et al., “Both L- and D-isomers of Allotrap 2702 Prolong Cardiac Allograft Survival in Mice,”J. Heart Lung Transplant. 15(1):78-87 (1996).
Gorochov, G., et al., “Perturbation of CD4+ and CD8+ T-cell reportoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy,”Nat. Med. 4(2):215-221 (Feb. 1998).
Grassy, G., et al., “Computer-assisted Rational Design of Immunosuppressive Compounds,”Nat Biotechnol. 16(8):748-752 (1998).
Grassy, G., et al., “Variable mapping of structure-activity relationships: Application to 17-spirolactone derivatives with mineralocorticoid activity,”J. Mol. Graph. 13(6):356-357 (Dec. 1995).
Guillemard, E., et al., “Interkeukin-7 and infection itself by human immunodeficiency virus 1 favor virus persistence in mature CD4+CD8−CD3+thymocytes through sustained induction of Bcl-2,”Blood98(7):2166-2174 (Oct. 2001).
Haiech, J., et al., “Use of TSAR as a new tool to analyze the molecular dynamics trajectories of proteins,”J. Mol. Graph. 13(1):46-48 (Feb. 1995).
Haslett, P., et al., “Thalidomide Stimulates T Cell Responses and Interleukin 12 Production in HIV-Infected Patients,”AIDS Res. Hum. Retroviruses15(13):1169-1179 (1999).
Heguy, A., et al., “Isolation and characterization of the fungal metabolite 3-O-methylviridicatin as an inhibitor of tumour necrosis factor α-induced human immunodeficiency virus replication,”Antivir. Chem. Chemother. 9(2):149-155 (Mar. 1998).
Hejdeman, B., et al., “Clinical and Immunological Benefits from Highly Active Antiretroviral Therapy in Spite of Limited Viral Load Reduction in HIV Type 1 Infection,”AIDS Res. Hum. Retroviruses17(4):277-286 (2001).
Herbein, G., et al., “Tumor necrosis factor α inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor,”J. Virol. 70(11):7388-7397 (Nov. 1996).
Imlach, S., et al., “Activated Peripheral CD8 Lymphocytes Express CD4 In Vivo and Are Targets for Infection by Human Immunodeficiency Virus Type 1,”J. Virol. 75(23):11555-11564 (Dec. 2001).
Iyer, S., et al., “Characterization and Biological Significance of Immunosuppressive Peptide D2702.75-84 (E—V) Binding Protein,”J. Biol. Chem. 273(5):2692-2697 (Jan. 1998).
Iyer, S. et al., “Inhibition of Tumor Necrosis Factor mRNA Translation by a Rationally Designed Immunomodulatory Peptide,”J. Biol. Chem. 275(22):17051-17057 (2000).
Iyer, S., et al., “Rational design and development of RDP58,”Curr. Pharm. Des. 8(24):2217-2229 (Nov. 2002).
Kaminski, M., et al., “AIDS Wasting Syndrome as an Entero-Metabolic Disorder: The Gut Hypothesis,”Alt. Med. Rev. 3(1):40-53 (1998).
Kaslow, R., et al., “Polymorphisms in HLA Class I Genes Associated with both Favorable Prognosis of Human Immunodeficiency Virus (HIV) Type 1 Infection and Positive Cytotoxic T-Lymphocyte Responses to ALVAC-HIV Recombinant Canarypox Vaccines,”J. Virol. 75(18):8681-8689 (Sep. 2001).
Kotler, D., “

Affiliated with

Also associated with

Rating

Combined therapy for treatment of HIV infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combined therapy for treatment of HIV infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined therapy for treatment of HIV infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3661764